Crypto World
Centene (CNC) Stock Plunges 14% as CEO Warns of Massive ACA Enrollment Decline
TLDR
- Shares of Centene plummeted 14% Tuesday, claiming the title of S&P 500’s biggest loser for the session
- Membership in ACA programs projected to decline to 3.5 million members by Q1 conclusion, a steep fall from December’s 5.5 million
- Management stood by its 2026 adjusted EPS forecast of above $3
- Mizuho Securities downgraded its price objective from $47 down to $41 while keeping a Neutral stance
- Medicare Advantage operations continue to operate at a loss and won’t reach profitability until after 2026
Investors in Centene have experienced a turbulent 2026, and Tuesday’s trading session only amplified the pain. The managed care provider’s shares tumbled 14% following remarks made by CEO Sarah London during her presentation at the Barclays Global Healthcare Conference, where her disclosure about plunging enrollment figures sent shockwaves through the market.
During her presentation, London informed conference participants that all three primary business segments at Centene continue to perform in line with 2026 projections. She confirmed the company’s adjusted earnings forecast of more than $3 per share — a figure that aligns precisely with the $3 consensus among analysts tracked by FactSet.
However, the market response was far from positive. With the guidance failing to deliver any upward revision, market participants focused their attention on the troubling membership trends.
The health insurer now projects ACA marketplace enrollment will sink to 3.5 million by the conclusion of the first quarter, representing a dramatic decrease from the 5.5 million members it had in December. As of the most recent February data, enrollment stood at 3.6 million participants.
London revealed that company leadership had predicted the overall marketplace would contract “somewhere between the high teens and the mid-thirties” on a percentage basis. She noted Centene anticipated finishing “at the higher end of that and possibly higher than the top end of that.”
She explained that some of the membership decline stems from strategic pricing adjustments implemented at year’s start, where the company chose to emphasize profitability enhancement rather than expanding its member base.
Medicare Advantage Still a Drag
The Medicare Advantage segment at Centene remains a significant headwind for overall performance. Profitability in this division was negative throughout 2025 and is projected to stay marginally unprofitable during 2026, with management targeting break-even status by 2027.
Adding to market uncertainty is the pending final rate announcement from the Centers for Medicare and Medicaid Services, scheduled for release by April 6 at the latest. The Trump administration’s earlier proposal to maintain essentially flat Medicare reimbursement rates for 2027 triggered widespread selling in Centene shares and throughout the managed care sector.
London disclosed that Centene had filed formal commentary with CMS regarding the Advance Rate Notice and voiced optimism that the final rate schedule would more appropriately account for current medical cost inflation trends affecting the entire industry.
Analyst Reaction
Mizuho responded swiftly following the conference presentation. The investment firm reduced its price objective on Centene shares to $41 from the previous $47 while maintaining its Neutral rating.
Mizuho pointed to worries surrounding health insurance marketplace attrition and specialty pharmaceutical cost pressures. The firm indicated it would employ a more cautious valuation approach until greater visibility emerges regarding the ultimate severity of the enrollment deterioration.
Truist Securities adopted a more constructive perspective, preserving its Buy recommendation with a $49 price objective, highlighting margin expansion potential and confidence from executive leadership. Cantor Fitzgerald maintained its Neutral position with a $41 target, characterizing the 2026 operating landscape as difficult.
For perspective, Centene shares have declined 9.7% during 2026, compared to a modest 0.7% pullback for the broader S&P 500 index.
Despite the selloff, the stock has actually outperformed several competitors. Molina Healthcare has retreated 17% year-to-date, Elevance Health is off 18%, and UnitedHealth Group has lost 14%.
Centene’s fourth quarter 2025 results revealed an adjusted diluted loss per share of $1.19, which marginally surpassed expectations for a $1.22 loss. Total revenue reached $49.73 billion, exceeding the anticipated $48.39 billion.
InvestingPro estimates Centene’s fair value at $62.11, with Wall Street analysts forecasting full-year 2026 EPS of $3.05.
